|  | Placebo | Piroxicam | p |
---|---|---|---|---|
Clinical evolution (number of patients) | Â | Â | Â | Â |
 | Return to premorbid clinical status | 6 | 10 | 0.127* |
 | Persistent decrease in clinical status | 8 | 4 |  |
Side effects (attributable to NSAID) | Â | Â | Â | Â |
 | None | 13 | 8 | 0.075* |
 | Possible | 1 | 3 |  |
 | Probable | 0 | 3 |  |
Length of stay (days; median, range) |  | 24.5 (19-64) | 29.0 (9-75) | 0.836†|
Death | Â | 1 | 2 | 0.541* |